Vnitr Lek 1993, 39(4):385-400
[Therapy of refractory multiple myeloma. II. Therapy using high doses of alkylating cytostatic agents and radiotherapy in addition to interferon and bone marrow transplantation].
- II. interní klinika Fakultní nemocnice Brno-Bohunice.
Klíčová slova: Bone Marrow Transplantation; Combined Modality Therapy; Humans; Interferon-alpha, therapeutic use, ; Melphalan, administration & dosage, ; Multiple Myeloma, radiotherapy,
The author presents part II of his review on the treatment of refractory myeloma. Treatment with large doses of melphalane, 140 mg/m2, was associated with a high death rate and therefore it is used nowadays only in combination with autologous transplantation or treatment with leucocytic growth factors (GM-CSF and G-CSF). Medium doses of melphalane (25 mg/m2 to 70 mg/m2) are tolerated better and are one of the possible approaches. Another possible therapeutic procedure is whole-body irradiation. The advantage of extensive irradiation is rapid regression of pain. Interferon-alpha achieves a therapeutic response in some 20% of refractory patients. Finally the author presents some data on transplantation of bone marrow in patients with multiple myeloma.
Keywords: Bone Marrow Transplantation; Combined Modality Therapy; Humans; Interferon-alpha /therapeutic use/; Melphalan /administration & dosage/; Multiple Myeloma /radiotherapy/
Zveřejněno: 1. duben 1993 Zobrazit citaci
| ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |